Cencora Lifts Annual Profit Outlook Despite Quarterly Miss
Cencora raised its annual profit forecast on Wednesday despite missing quarterly estimates. The firm expects demand for specialty and GLP-1 drugs to drive growth.
Xurve View
Insights:
Xurve View
CENCORA INC raised its annual profit forecast to $17.65-$17.90 per share despite missing second-quarter earnings and revenue estimates. The distributor is pivoting toward high-margin specialty medicines and GLP-1 drugs to offset price cuts on branded products. Investors are pricing in resilient demand for complex therapies even as traditional drug distribution faces volume headwinds.
